GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has moved ahead to make the pronouncement that it will be undertaking data presentation from the  pivotal Phase 3 trials of Epidiolex® (cannabidiol oral solution).

It is hoped that the new medication will be helpful in handling Dravet syndrome and Lennox-Gastaut syndrome (LGS).There will also be great need to scrutinize other supportive data especially the one emanating from the Annual Meeting of the American Academy of Neurology (AAN) that will be conducted in Los Angeles, California.

GW’s Chief Executive Officer Justin Gover while moving out of a business conference that was held recently came across several journalists who wanted him to crack up regarding the latest developments in the company.

He delved deeper into the matter to state that the regulatory applications for Epidiolex had already considered for review in both Europe and in the U.S. If all moves according to plan, it is expected that it might end up being launched in the second half of this year and it will indeed turn out to be an revolutionary period for the company as well as those persons awaiting the new potential treatment option.]

A person following closely on the latest developments of the company but who wanted his identity shielded for reasons best known to him outlined that Epidiolex would in the long run play a significant role helping treat a number of the  rare childhood-onset epilepsy disorders. He added that it was a good thing that the company had proceeded to submit a New Drug Application with the FDA for Epidiolex as an adjunctive treatment that would be moving quite a long way handling seizures associated with Dravet syndrome and LGS.

It is also worth noting that the current times are witnessing lot of significant changes and shifts in the business dynamics. Business rivalry has been taken to a complete new level and experts have moved ahead to attribute that to the technological advancements that have been sweeping fast across the globe.

It is also a good thing that the Company is currently undertaking the evaluation of additional clinical development programs in a wide range of the orphan seizure disorders.